THC Global operates under a ‘Farm to Pharma’ pharmaceutical model.
() has been granted a trading halt by the ASX pending the release of information regarding the grant of a manufacture licence by the Office of Drug Control.
Shares in the company will remain halted until the earlier of either, the release of relevant information, or, the commencement of trading next Tuesday 9 July 2019.
THC is in a prime position to commence medicinal cannabis production to service both domestic patients and the global export market.
The company is active globally with operations in Australia, New Zealand, and Canada and partnerships across Europe, Asia, and the Middle East.
In addition to its core Australian medicinal cannabis assets, THC has a significant Canadian presence – both in cannabis and in hydroponics equipment.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of THC Global Group Ltd named herein, including the promotion by the Company of THC Global Group Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE